Gene Therapy Using Adeno-associated Virus Vectors

Overview

Journal Clin Microbiol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2008 Oct 16

PMID 18854481

Citations 417

Authors

Shyam Daya

Kenneth I Berns

Affiliations

Soon will be listed here.

Abstract

The unique life cycle of adeno-associated virus (AAV) and its ability to infect both nondividing and dividing cells with persistent expression have made it an attractive vector. An additional attractive feature of the wild-type virus is the lack of apparent pathogenicity. Gene transfer studies using AAV have shown significant progress at the level of animal models; clinical trials have been noteworthy with respect to the safety of AAV vectors. No proven efficacy has been observed, although in some instances, there have been promising observations. In this review, topics in AAV biology are supplemented with a section on AAV clinical trials with emphasis on the need for a deeper understanding of AAV biology and the development of efficient AAV vectors. In addition, several novel approaches and recent findings that promise to expand AAV's utility are discussed, especially in the context of combining gene therapy ex vivo with new advances in stem or progenitor cell biology.

Citing Articles

AAV Capsid Modification and Its Influence on Viral Protein Stoichiometry and Packaging Fitness: Current Understandings and Future Direction.

Dogbey D, Barth S Mol Biotechnol. 2025; .

PMID: 39881109 DOI: 10.1007/s12033-025-01381-0.

Viral-based gene therapy clinical trials for immune deficiencies and blood disorders from 2013 until 2023 - an overview.

Eshghi S, Mousakhan Bakhtiari M, Behfar M, Izadi E, Naji P, Jafari L Regen Ther. 2025; 28():262-279.

PMID: 39844821 PMC: 11751425. DOI: 10.1016/j.reth.2024.12.007.

In Vivo Selection of S/MAR Sequences to Favour AAV Episomal Maintenance in Dividing Cells.

Llanos-Ardaiz A, Lantero A, Neri L, Mauleon I, Ruiz de Galarreta M, Trigueros-Motos L Int J Mol Sci. 2024; 25(23).

PMID: 39684442 PMC: 11641770. DOI: 10.3390/ijms252312734.

Revolutionizing cancer treatment: the emerging potential and potential challenges of self-processed CAR cell therapy.

Lv R, Guo Y, Liu W, Dong G, Liu X, Li C Theranostics. 2024; 14(19):7424-7447.

PMID: 39659573 PMC: 11626932. DOI: 10.7150/thno.101941.

Adeno-associated virus serotype 2 capsids with proteolytic cuts by trypsin remain intact and potent.

Zhou Y, Sach T, Ong J, Lim T, Berecz Z, Deniston C Gene Ther. 2024; .

PMID: 39613903 DOI: 10.1038/s41434-024-00507-4.

References

Summerford C, Bartlett J, Samulski R . AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med. 1999; 5(1):78-82. DOI: 10.1038/4768. View

Rizzuto G, Gorgoni B, Cappelletti M, Lazzaro D, Gloaguen I, Poli V . Development of animal models for adeno-associated virus site-specific integration. J Virol. 1999; 73(3):2517-26. PMC: 104499. DOI: 10.1128/JVI.73.3.2517-2526.1999. View

Bartlett J, Kleinschmidt J, Boucher R, Samulski R . Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol. 1999; 17(2):181-6. DOI: 10.1038/6185. View

Brockstedt D, Podsakoff G, Fong L, Kurtzman G, MUELLER-RUCHHOLTZ W, Engleman E . Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol. 1999; 92(1):67-75. DOI: 10.1006/clim.1999.4724. View

Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J . Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999; 6(9):1574-83. DOI: 10.1038/sj.gt.3300994. View

Hauck B, Zhao W, High K, Xiao W . Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adeno-associated virus transduction. J Virol. 2004; 78(24):13678-86. PMC: 533901. DOI: 10.1128/JVI.78.24.13678-13686.2004. View

Kashiwakura Y, Tamayose K, Iwabuchi K, Hirai Y, Shimada T, Matsumoto K . Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol. 2004; 79(1):609-14. PMC: 538679. DOI: 10.1128/JVI.79.1.609-614.2005. View

Bleker S, Sonntag F, Kleinschmidt J . Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J Virol. 2005; 79(4):2528-40. PMC: 546590. DOI: 10.1128/JVI.79.4.2528-2540.2005. View

Gao G, Vandenberghe L, Wilson J . New recombinant serotypes of AAV vectors. Curr Gene Ther. 2005; 5(3):285-97. DOI: 10.2174/1566523054065057. View

10.

Liu X, Luo M, Zhang L, Yan Z, Zak R, Ding W . Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells. Hum Gene Ther. 2005; 16(9):1116-23. DOI: 10.1089/hum.2005.16.1116. View

11.

Schnepp B, Jensen R, Chen C, Johnson P, Clark K . Characterization of adeno-associated virus genomes isolated from human tissues. J Virol. 2005; 79(23):14793-803. PMC: 1287572. DOI: 10.1128/JVI.79.23.14793-14803.2005. View

12.

Fischer A, Hacein-Bey-Abina S, Lagresle C, Garrigue A, Cavazana-Calvo M . [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome]. Bull Acad Natl Med. 2006; 189(5):779-85. View

13.

Ghosh A, Yue Y, Duan D . Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J Gene Med. 2005; 8(3):298-305. PMC: 2581716. DOI: 10.1002/jgm.835. View

14.

Akache B, Grimm D, Shen X, Fuess S, Yant S, Glazer D . A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol Ther. 2007; 15(2):330-9. PMC: 7106033. DOI: 10.1038/sj.mt.6300053. View

15.

Yamamoto N, Suzuki M, Kawano M, Inoue T, Takahashi R, Tsukamoto H . Adeno-associated virus site-specific integration is regulated by TRP-185. J Virol. 2006; 81(4):1990-2001. PMC: 1797547. DOI: 10.1128/JVI.02014-06. View

16.

Zhao W, Wu J, Zhong L, Srivastava A . Adeno-associated virus 2-mediated gene transfer: role of a cellular serine/threonine protein phosphatase in augmenting transduction efficiency. Gene Ther. 2006; 14(6):545-50. DOI: 10.1038/sj.gt.3302886. View

17.

Wu J, Zhao W, Zhong L, Han Z, Li B, Ma W . Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of rep proteins in vector purity. Hum Gene Ther. 2007; 18(2):171-82. DOI: 10.1089/hum.2006.088. View

18.

Li H, Murphy S, Giles-Davis W, Edmonson S, Xiang Z, Li Y . Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther. 2007; 15(4):792-800. DOI: 10.1038/sj.mt.6300090. View

19.

Wang L, Figueredo J, Calcedo R, Lin J, Wilson J . Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther. 2007; 18(3):185-94. DOI: 10.1089/hum.2007.001. View

20.

Mingozzi F, Maus M, Hui D, Sabatino D, Murphy S, Rasko J . CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007; 13(4):419-22. DOI: 10.1038/nm1549. View